Pub Date : 2025-12-06DOI: 10.1016/j.ad.2025.104527
R.P. Román Cheuque, D. Jiménez-Gallo, I. Villegas Romero, M. Linares Barrios
{"title":"A Rare Case of Acquired Reactive Perforating Collagenosis in a Child With Type 1 Diabetes","authors":"R.P. Román Cheuque, D. Jiménez-Gallo, I. Villegas Romero, M. Linares Barrios","doi":"10.1016/j.ad.2025.104527","DOIUrl":"10.1016/j.ad.2025.104527","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104527"},"PeriodicalIF":2.8,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/j.ad.2025.104531
M. Mansilla-Polo , M. Pons-Benavent , P. Fernández-Crehuet , E. Vilarrasa , C. Albanell-Fernández , E. Morales-Tedone , F. Rausell-Félix , R. Alcalá-García , M. Matellanes-Palacios , G. Martín-Ezquerra , F. Alfageme , C. Ciudad-Blanco , M.T. López-Villaescusa , J.M. Segura-Palacios , J.C. Pascual-Ramírez , M.L. Fernández-Díaz , D. Falkenhain-López , M. García-Gil , A. Agustí-Mejías , N. No-Pérez , A. Molina-Leyva
Background
Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidradenitis suppurativa (HS).
Objectives
To assess the safety and efficacy profile of bimekizumab in patients with moderate-to-severe HS across multiple centers in Spain.
Methods
We conducted a retrospective cohort study including 84 patients treated with bimekizumab. Efficacy was assessed using an intention-to-treat approach, with patients who discontinued treatment for any reason or were lost to follow-up considered nonresponders. Data were collected at baseline, week 16, and week 24.
Results
The analysis included a total of 84 patients at 16 weeks, with 43 having completed the 24-week follow-up assessment (56 men [66.67%] and 28 women [33.33%]) with a mean age of 44.17 (13.43) years and a mean baseline IHS4 of 23.75 (12.87) were included. By week 24, IHS4 scores dropped by 16.73 points (p < 0.0001); a HiSCR50 of 55.95% was achieved at week 16, which was maintained with a HiSCR50 of 55.81% at week 24; DLQI scores improved by 10.67 points (p < 0.0001); pain scores dropped by 3.42 points (p < 0.0001); and flare counts were reduced by 1.53 (p = 0.0006). Adverse events were reported in 20.24% of patients by week 16, mainly candidiasis, and dropped to 11.90% by week 24. 53.57% (45/84) of patients achieved IHS4-55 by week 16, and by week 24, 60.47% (26/43) of patients maintained or reached this response level.
Conclusions
Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.
{"title":"Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study","authors":"M. Mansilla-Polo , M. Pons-Benavent , P. Fernández-Crehuet , E. Vilarrasa , C. Albanell-Fernández , E. Morales-Tedone , F. Rausell-Félix , R. Alcalá-García , M. Matellanes-Palacios , G. Martín-Ezquerra , F. Alfageme , C. Ciudad-Blanco , M.T. López-Villaescusa , J.M. Segura-Palacios , J.C. Pascual-Ramírez , M.L. Fernández-Díaz , D. Falkenhain-López , M. García-Gil , A. Agustí-Mejías , N. No-Pérez , A. Molina-Leyva","doi":"10.1016/j.ad.2025.104531","DOIUrl":"10.1016/j.ad.2025.104531","url":null,"abstract":"<div><h3>Background</h3><div>Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidradenitis suppurativa (HS).</div></div><div><h3>Objectives</h3><div>To assess the safety and efficacy profile of bimekizumab in patients with moderate-to-severe HS across multiple centers in Spain.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study including 84 patients treated with bimekizumab. Efficacy was assessed using an intention-to-treat approach, with patients who discontinued treatment for any reason or were lost to follow-up considered nonresponders. Data were collected at baseline, week 16, and week 24.</div></div><div><h3>Results</h3><div>The analysis included a total of 84 patients at 16 weeks, with 43 having completed the 24-week follow-up assessment (56 men [66.67%] and 28 women [33.33%]) with a mean age of 44.17 (13.43) years and a mean baseline IHS4 of 23.75 (12.87) were included. By week 24, IHS4 scores dropped by 16.73 points (<em>p</em> <!--><<!--> <!-->0.0001); a HiSCR50 of 55.95% was achieved at week 16, which was maintained with a HiSCR50 of 55.81% at week 24; DLQI scores improved by 10.67 points (<em>p</em> <!--><<!--> <!-->0.0001); pain scores dropped by 3.42 points (<em>p</em> <!--><<!--> <!-->0.0001); and flare counts were reduced by 1.53 (<em>p</em> <!-->=<!--> <!-->0.0006). Adverse events were reported in 20.24% of patients by week 16, mainly candidiasis, and dropped to 11.90% by week 24. 53.57% (45/84) of patients achieved IHS4-55 by week 16, and by week 24, 60.47% (26/43) of patients maintained or reached this response level.</div></div><div><h3>Conclusions</h3><div>Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104531"},"PeriodicalIF":2.8,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ad.2025.104523
A. Fernandez-Flores , J. García Silva
{"title":"Male-pattern Androgenetic Alopecia in Women on Hormonal Treatment: Further Evidence for a Dual Male–Female Pathogenic Mechanism","authors":"A. Fernandez-Flores , J. García Silva","doi":"10.1016/j.ad.2025.104523","DOIUrl":"10.1016/j.ad.2025.104523","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104523"},"PeriodicalIF":2.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.ad.2025.104525
R. Rivera-Díaz , B. Joven , A. Gotor-Rivera , J. Hernández
Background and objectives
Plaque psoriasis (Pso) and hidradenitis suppurativa (HS) are chronic inflammatory diseases associated with multiple comorbidities, including cardiovascular conditions, which may negatively impact survival. The aim of this study was to analyze mortality in patients with Pso and HS vs the general population and to each other, as well as the potential impact of biologic therapy on mortality.
Materials and methods
We conducted a retrospective cohort study based on electronic health records retrieved from the TriNetX platform. Patients diagnosed with Pso or HS, with or without biologic therapy, were compared with matched cohorts from the general population and with each other. Cohorts were matched using propensity score matching (PSM) and adjusted for age, sex, and comorbidities potentially affecting mortality, including smoking, diabetes, hyperlipidemia, hypertension, overweight and obesity, cardiovascular disease, pulmonary embolism, venous thrombosis, ischemic heart disease, and cerebrovascular disease. The mortality incidence rate was assessed using risk ratio (RR) and hazard ratio (HR), with 95% confidence intervals (CIs) during a 10-year follow-up.
Results
After adjustment, 76,191 patients with Pso and 52,354 with HS were included. Compared to the general population, patients with Pso showed a higher mortality risk (RR, 2.25; 95%CI, 2.18–2.32; HR, 2.02; 95%CI, 1.95–2.08), with a significant reduction in those treated with biologics (RR, 0.76; 95%CI, 0.70–0.83; HR, 0.62; 95%CI, 0.57–0.67). Similarly, patients with HS also exhibited a higher mortality risk (RR, 2.25; 95%CI, 2.14–2.37; HR, 2.28; 95%CI, 2.16–2.40), which was attenuated in those treated with biologics (RR, 0.80; 95%CI, 0.65–0.99; HR, 0.62; 95%CI, 0.49–0.77). When comparing both diseases, patients with HS had a higher mortality risk vs those with Pso (HR, 1.16; 95%CI, 1.11–1.22). The same trend was observed in biologic-treated subgroups (RR, 1.30; 95%CI, 1.00–1.68; HR, 1.45; 95%CI, 1.12–1.90).
Conclusions
Both psoriasis (pso) and hidradenitis suppurativa (hs) are associated with an increased risk of mortality, which appears to be mitigated by biologic therapy. Early and comprehensive management of these conditions, including systemic inflammation control and comorbidity screening, may improve survival outcomes.
{"title":"Mortality Outcomes in Patients With Plaque Psoriasis and Hidradenitis Suppurativa: The Role of Biologic Therapy","authors":"R. Rivera-Díaz , B. Joven , A. Gotor-Rivera , J. Hernández","doi":"10.1016/j.ad.2025.104525","DOIUrl":"10.1016/j.ad.2025.104525","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Plaque psoriasis (Pso) and hidradenitis suppurativa (HS) are chronic inflammatory diseases associated with multiple comorbidities, including cardiovascular conditions, which may negatively impact survival. The aim of this study was to analyze mortality in patients with Pso and HS vs the general population and to each other, as well as the potential impact of biologic therapy on mortality.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective cohort study based on electronic health records retrieved from the TriNetX platform. Patients diagnosed with Pso or HS, with or without biologic therapy, were compared with matched cohorts from the general population and with each other. Cohorts were matched using propensity score matching (PSM) and adjusted for age, sex, and comorbidities potentially affecting mortality, including smoking, diabetes, hyperlipidemia, hypertension, overweight and obesity, cardiovascular disease, pulmonary embolism, venous thrombosis, ischemic heart disease, and cerebrovascular disease. The mortality incidence rate was assessed using risk ratio (RR) and hazard ratio (HR), with 95% confidence intervals (CIs) during a 10-year follow-up.</div></div><div><h3>Results</h3><div>After adjustment, 76,191 patients with Pso and 52,354 with HS were included. Compared to the general population, patients with Pso showed a higher mortality risk (RR, 2.25; 95%CI, 2.18–2.32; HR, 2.02; 95%CI, 1.95–2.08), with a significant reduction in those treated with biologics (RR, 0.76; 95%CI, 0.70–0.83; HR, 0.62; 95%CI, 0.57–0.67). Similarly, patients with HS also exhibited a higher mortality risk (RR, 2.25; 95%CI, 2.14–2.37; HR, 2.28; 95%CI, 2.16–2.40), which was attenuated in those treated with biologics (RR, 0.80; 95%CI, 0.65–0.99; HR, 0.62; 95%CI, 0.49–0.77). When comparing both diseases, patients with HS had a higher mortality risk vs those with Pso (HR, 1.16; 95%CI, 1.11–1.22). The same trend was observed in biologic-treated subgroups (RR, 1.30; 95%CI, 1.00–1.68; HR, 1.45; 95%CI, 1.12–1.90).</div></div><div><h3>Conclusions</h3><div>Both psoriasis (pso) and hidradenitis suppurativa (hs) are associated with an increased risk of mortality, which appears to be mitigated by biologic therapy. Early and comprehensive management of these conditions, including systemic inflammation control and comorbidity screening, may improve survival outcomes.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104525"},"PeriodicalIF":2.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号